<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15224">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02908685</url>
  </required_header>
  <id_info>
    <org_study_id>BP39055</org_study_id>
    <secondary_id>2016-000750-35</secondary_id>
    <nct_id>NCT02908685</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7034067 in Type 2 and 3 Spinal Muscular Atrophy Participants (Sunfish)</brief_title>
  <official_title>A Two-Part Seamless, Multi-Center Randomized, Placebo-Controlled, Double-blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7034067 in Type 2 and 3 Spinal Muscular Atrophy Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      Multi-center, randomized, double-blind, placebo-controlled, Phase II study to assess the
      safety, tolerability, pharmacokinetic, pharmacodynamics, and efficacy of RO7034067 in adult
      and pediatric patients with Type 2 and Type 3 spinal muscular atrophy (SMA). The study
      consists of two parts, an exploratory dose finding part (Part 1) of RO7034067 for 12-weeks
      and a confirmatory part (Part 2) of RO7034067 for 24-months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2016</start_date>
  <completion_date type="Anticipated">March 6, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 2: Change from baseline in the total motor function measure 32 (MFM-32) score at Month 12</measure>
    <time_frame>Baseline (Day -1) and Month 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Recommended Part 2 Dose of RO7034067</measure>
    <time_frame>120 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood</measure>
    <time_frame>Part 2: Days -1, 1, 7, 28, 120, 246, 365, 729</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival of Motor Neuron (SMN) Protein Levels in Blood</measure>
    <time_frame>Part 2: Days -1, 7, 28, 120, 246, 365, 729</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve Stabilization or Improvement (Defined as &gt;= 0) in the Total Motor function measure (MFM) Score at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Vital Capacity (FVC) at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Peak Cough Flow (PCF) at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Neuromuscular Disease Domain Score as Assessed by Pediatric Quality of Life Inventory (PedsQL) 3.0 Neuromuscular Module at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Score of the PedsQL 4.0 Generic Core Scale at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Experience at Least one Disease Related Adverse Event</measure>
    <time_frame>Baseline up to Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Maximum plasma concentration (Cmax) of RO7034067</measure>
    <time_frame>Part 1 and 2: 1, 2, 4, 6 hours post dose on Day 1; Pre-dose (Hour 0) on Days 7, 14, 56 (part 2), 120, 246, 490, 729; pre-dose (Hour 0) and 1, 2, 4, 6 hours post dose on Days 28, 56 (part 1), 365, 609</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Area under the curve (AUC) of RO7034067</measure>
    <time_frame>Part 1 and 2: 1, 2, 4, 6 hours post dose on Day 1; Pre-dose (Hour 0) on Days 7, 14, 56 (part 2), 120, 246, 490, 729; pre-dose (Hour 0) and 1, 2, 4, 6 hours post dose on Days 28, 56 (part 1), 365, 609</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Concentration at the end of a dosing interval (Ctrough) of RO7034067</measure>
    <time_frame>Part 1 and 2: Pre-dose (Hour 0) on Days 7, 14, 28, 56, 120, 246, 365, 490, 609, 729</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the MFM Domain 1 (D1) Score at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the MFM Domain 2 (D2) Score at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the MFM Domain 3 (D3) Score at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score</measure>
    <time_frame>Baseline (Day-1), Day 120, Day 248, Day 386, Day 647, Day 729</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Muscular Atrophy, Spinal</condition>
  <arm_group>
    <arm_group_label>Part 1 Group A: Adolescents and Adults (RO7034067)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adolescent and adult participants aged 12-25 years will receive RO7034067 for 12 weeks. Once 12-week treatment is completed and Part 2 dose is established, participants will be switched to Part 2 dose and will be followed-up in open label extension (OLE) phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Group A: Adults and Adolescents (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Adolescent and adult participants aged 12-25 years will receive placebo matching to RO7034067 for 12 weeks. Once 12-week treatment is completed placebo participants will be will be given the choice to switch to active treatment in OLE phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Group B: Children (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Children aged 2-11 years will receive placebo matching to RO7034067 for 12 weeks. Once 12-week treatment is completed placebo participants will be will be given the choice to switch to active treatment in OLE phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Group B: Children (RO7034067)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children aged 2-11 years will receive RO7034067 for 12 weeks. Once 12-week treatment is completed and Part 2 dose is established, participants will be switched to Part 2 dose and will be followed-up in OLE phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants aged 2-25 years will receive placebo matching to RO7034067. After 12-month primary analysis (to be performed once the last participant completes the 12-month treatment), placebo participants will be switched to active treatment (RO7034067). After 24-month treatment, participants will be offered the opportunity to enter the OLE phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: RO7034067</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 2-25 years will receive RO7034067 at the dose decided during Part 1 of the study, for up to 24 months. After 24-month treatment, participants will be offered the opportunity to enter the OLE phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered orally.</description>
    <arm_group_label>Part 1 Group A: Adolescents and Adults (RO7034067)</arm_group_label>
    <arm_group_label>Part 1 Group A: Adults and Adolescents (Placebo)</arm_group_label>
    <arm_group_label>Part 1 Group B: Children (Placebo)</arm_group_label>
    <arm_group_label>Part 1 Group B: Children (RO7034067)</arm_group_label>
    <arm_group_label>Part 2: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7034067</intervention_name>
    <description>RO7034067 will be administered orally.</description>
    <arm_group_label>Part 1 Group A: Adolescents and Adults (RO7034067)</arm_group_label>
    <arm_group_label>Part 1 Group A: Adults and Adolescents (Placebo)</arm_group_label>
    <arm_group_label>Part 1 Group B: Children (Placebo)</arm_group_label>
    <arm_group_label>Part 1 Group B: Children (RO7034067)</arm_group_label>
    <arm_group_label>Part 2: RO7034067</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For Part 1: Type 2 or 3 SMA ambulant or non-ambulant. For Part 2: Type 2 or 3 SMA
             non-ambulant

          -  Confirmed diagnosis of 5q-autosomal recessive SMA For Part 2: 1) revised upper limb
             module(RULM) entry item A greater than or equal to [&gt;=] 2; 2) ability to sit
             independently as assessed by item 9 of the motor function measure (MFM)

          -  Negative blood pregnancy test at screening and agreement to comply with measures to
             prevent pregnancy and restrictions on sperm donation

        Exclusion Criteria:

          -  Concomitant or previous participation in any investigational drug or device study
             within 90 days prior to screening, or 5 half-lives of the drug, whichever is longer

          -  Concomitant or previous participation at any time in a Survival of motor neuron
             (SMN)-2 targeting antisense oligonucleotide, SMN2 splicing modifier or gene therapy
             study

          -  Any history of cell therapy

          -  Hospitalization for a pulmonary event within the last 2 months or planned at time of
             screening

          -  Surgery for scoliosis or hip fixation in the one year preceding screening or planned
             within the next 18 months

          -  Unstable gastrointestinal, renal, hepatic, endocrine, or cardiovascular system
             diseases as considered to be clinically significant by the Investigator

          -  Presence of clinically significant electrocardiogram (ECG) abnormalities before study
             drug administration from average of triplicate measurement or cardiovascular disease
             indicating a safety risk for participants as determined by the Investigator

          -  Any major illness within one month before the screening examination or any febrile
             illness within one week prior to screening and up to first dose administration

          -  Any inhibitor of cytochrome P450 (CYP) 3A4 and/or any Organic Cation Transporter 2
             (OCT-2) and multidrug and toxin extrusion (MATE) substrates taken within 2 weeks
             and/or any inducer of CYP3A4 taken within 4 weeks (or within 5-times the elimination
             half-life, whichever is longer) prior to dosing or participants taking any nutrients
             known to modulate CYP3A activity

          -  Recently initiated treatment (within less than [&lt;] 6 months prior to randomization)
             with oral salbutamol or another beta 2-adrenergic agonist taken orally

          -  Any prior use of chloroquine, hydroxychloroquine, retigabin, vigabatrin or
             thioridazine, is not allowed - Ascertained or presumptive hypersensitivity (e.g.,
             anaphylactic reaction) to RO7034067 or to the constituents of its formulation

          -  Recent history (less than one year) of ophthalmological diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: BP39055 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connecticut Children'S Medical Center; Dept of Neurology</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ann and Robert H. Lurie Children Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke Clin Rsch Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science Uni</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Utah Clinical Neurosciences Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Pediatria Dr. Garrahan; Inmunologia</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1245</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sydney Children's Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chr de La Citadelle</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital Division of Pediatric Neurology</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Femme Mere Enfant; Medecine Physique et Readaptation Pediatrique - L'ESCALE</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Armand Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen; Klinik für Kinderheilkunde I</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg; Klinik für Neuropädiatrie und Muskelerkrankungen</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Pediatrico Bambino Gesù; U.O. Malattie Neuromuscolari e Neurodegenerative</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico Agostino Gemelli; Dipartimento di Neuropsichiatria Infantile</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Giannina Gaslini; U.O.S.D. Centro di Miologia e Patologie Neurodegenerative</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Unità Operativa Complessa di Neurologia</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Neurologico &quot;Carlo Besta&quot;; UO di Neurologia dello Sviluppo</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico G.Martino; Dip. Neurologia e Malattie neuromuscolari</name>
      <address>
        <city>Messina</city>
        <state>Sicilia</state>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan De Deu</name>
      <address>
        <city>Esplugues De Llobregas</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron; Servicio de Reumatologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>280146</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset, Östra Sjukhus; Drottning Silvias Barnsjukhus</name>
      <address>
        <city>Göteborg</city>
        <zip>416 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitäts-Kinderspitalbeider Basel_Abteilung für Neuro- und Entwicklungspädiatrie</name>
      <address>
        <city>Basel</city>
        <zip>4005</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Hospital; Pediatric Neurology</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hacettepe University, School of Medicine; Pediatrics Department; Pediatrics Child Neurology Unit</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Newcastle upon Tyne Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 3, 2017</lastchanged_date>
  <firstreceived_date>September 19, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
